Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: RXGOLF who wrote (18667)	4/5/1998 6:57:00 PM
From: Proton	Read Replies (2) \| Respond to of 32384

Re: Second can be Gold, Sometimes Good Luck, and at least this might be considered on topic (:- ). Anything is better than that mortally tedious cyberfeministic nonsense with which we've had to contend over the last few days. As I mentioned to Henry, the best case scenario is that Targretin is recognized for its synergistic effects with Tamoxifen. If this fact can reach Wall Street's radar, Ligand can avoid the "but we're better than Tamoxifen" argument in favor of "this makes Tamoxifen even better." Well, here's to bundles! And to more scintillating exchanges than the majority over the past few days. Pý